Is NeoGenomics (NEO) stock Halal?

NeoGenomics is a prominent player in the healthcare and pharmaceutical industry, specializing in cancer diagnostics and related genetic testing services. The company offers a comprehensive range of diagnostic services aimed at aiding in the precise determination of cancer-related conditions. These services include advanced pathology, genetic testing, and comprehensive genomic profiling, which play a crucial role in personalizing patient care by informing treatment strategies. For Muslim investors, though, the most pressing question is simpler: is NeoGenomics a Halal investment?

Is NeoGenomics Shariah compliant?

Yes. In the October 2026 screening NeoGenomics (NEO) passes AAOIFI Shariah Standard No. 21: the business activity screen and every financial ratio screen hold. Medicines and medical devices are permissible, and healthcare companies like NeoGenomics usually clear the activity screen comfortably. What AAOIFI Shariah Standard No. 21 watches is the financing behind the pipeline: drug development is expensive, and the 30% interest bearing debt cap decides the verdict more often than the science does.

Does NeoGenomics pass the business activity test?

Yes. In the October 2026 screening NeoGenomics holds an overall PASS, which a stock only earns when its core business clears the activity screen. Treating illness is permissible work; the scrutiny belongs to the financing behind it.

Is NeoGenomics' income Halal?

Yes, within AAOIFI's tolerance. NeoGenomics' income from non-permissible sources stays below 5% of revenue in the October 2026 screening, and the small impure portion is handled through purification: the factor of 99.4% tells holders of NEO what share of each dividend to keep and what remainder to donate to charity. On a dividend yield of around None, the purification amount is modest but real.

Does NeoGenomics meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation, measured against a market capitalisation of $2.39B (market data as of 1 October 2026). Because the caps move with the share price, our Shariah Supervisory Board has NEO re-screened every month, and the result above always shows the latest verdict.

Why do other halal screeners show a different verdict for NeoGenomics?

Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the screening method? Read What is Halal Investing? A Guide to Halal Stocks and Islamic Finance